Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMed

Depot-specific differences and heterogeneity of adipose-derived stem cells in diet-induced obesity.

Guo H., Sheng A., Qi X., Zhu L., Wang G., Zou Y.

Animal Study on Hip, published in Obesity (Silver Spring) (2024) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Obesity (Silver Spring) (2024)
Country
United States
Reported sample size
—
Source database
PubMed
PMID
39496515
DOI
10.1002/oby.24149
Citations
1

Abstract (original English)

Objective Obesity is a global health concern. Studying the heterogeneity of adipose-derived stem cells (ADSCs) plays a pivotal role in understanding metabolic disorders, such as obesity. Methods Mass cytometry was used to determine the depot-specific differences and heterogeneity of ADSCs and their alterations at the single-cell level in a diet-induced-obesity (DIO) model in which mice were treated with liraglutide. Results We characterized the relationship among ADSC markers and found that CD26 and CD142 could identify the most representative heterogeneous ADSCs in subcutaneous adipose tissue and visceral adipose tissue. Specifically, CD26 + CD142 - and CD26 + CD142 + ADSCs were exclusive to subcutaneous adipose tissue and visceral adipose tissue, respectively, whereas CD26 - CD142 + ADSCs were present in both. RNA analysis explored the potential functions of these three subgroups. In the visceral adipose tissue of DIO mice, we observed a substantial downregulation of CD26 + CD142 + ADSCs and upregulation of CD26 - CD142 + ADSCs, both of which were mitigated by liraglutide treatment. Conclusions Our study highlights the depot-specific differences and heterogeneity of ADSCs and their alterations under DIO conditions, which can potentially be reversed by liraglutide treatment. This study provides new insights into the identification of more specific ADSC subgroups to explore the

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsObesityMiceLiraglutideIntra-Abdominal FatMaleDiet, High-FatMice, Inbred C57BLStem CellsSubcutaneous Fat

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research